Health
Clinical trial testing efficacy of antibody against SARS-CoV-2 begins – Medical Xpress
The University of Chicago Medicine is launching a clinical trial to examine the potential of an antibody against the SARS-CoV-2 spike protein for treating COVID-19, the disease caused by the novel coronavirus.
The University of Chicago Medicine is launching a clinical trial to examine the potential of an antibody against the SARS-CoV-2 spike protein for treating COVID-19, the disease caused by the novel coronavirus.
For the BLAZE-1 trial, UChicago is recruiting 22 participants to be treated with the LY-CoV555 antibody developed by Eli Lilly and Company in collaboration with AbCellera. The antibody was first identified by scientists at the National Institute of Allergy and Infectious Diseases and AbCe…
-
General21 hours agoPope Leo XIV criticises nationalist politics at Sunday mass
-
Noosa News12 hours agoBike riders to cycle across the traffic lanes of the Story Bridge
-
General21 hours ago‘Miracle’ PM gets top gong in the name of the King
-
General11 hours agoHeroic surfing priest rescues father and son from rip at Cable Beach